Evidence map›Paper›PMID 32200419›Full record

ReviewArchives of gynecology and obstetrics2020

Ovarian cancer stem cells: ready for prime time?

Carlotta Sabini, Flavia Sorbi, Paula Cunnea, Christina Fotopoulou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of gynecology and obstetrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Carlotta SabiniDepartment of Biomedical, Experimental and Clinical Sciences, Division of Obstetrics and Gynecology, University of Florence, 50134, Florence, Italy.ORCID http://orcid.org/0000-0003-1068-8243
Flavia SorbiDepartment of Biomedical, Experimental and Clinical Sciences, Division of Obstetrics and Gynecology, University of Florence, 50134, Florence, Italy.ORCID http://orcid.org/0000-0001-7277-6420
Paula CunneaWest London Gynecological Cancer Centre, Imperial College NHS Trust, London, W12 OHS, UK.ORCID http://orcid.org/0000-0002-3699-4911
Christina FotopoulouWest London Gynecological Cancer Centre, Imperial College NHS Trust, London, W12 OHS, UK. chfotopoulou@gmail.com.ORCID http://orcid.org/0000-0001-6375-9645
University of Florence · ITImperial College London · GBLondon Cancer · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe role of cancer stem cells (CSC) remains controversial and increasingly subject of investigation as a potential oncogenetic platform with promising therapeutic implications. Understanding the role of CSCs in a highly heterogeneous disease like epithelial ovarian cancer (EOC) may potentially lead to the better understanding of the oncogenetic and metastatic pathways of the disease, but also to develop novel strategies against its progression and platinum resistance.

methodsWe have performed a review of all relevant literature that addresses the oncogenetic potential of stem cells in EOC, their mechanisms, and the associated therapeutic targets.

resultsCancer stem cells (CSCs) have been reported to be implicated not only in the development and pathways of intratumoral heterogeneity (ITH), but also potentially modulating the tumor microenvironment, leading to the selection of sub-clones resistant to chemotherapy. Furthermore, it appears that the enhanced DNA repair abilities of CSCs are connected with their endurance and resistance maintaining their genomic integrity during novel targeted treatments such as PARP inhibitors, allowing them to survive and causing disease relapse functioning as a tumor seeds.

conclusionsIt appears that CSCs play a major role in the underlying mechanisms of oncogenesis and development of relapse in EOC. Part of promising future plans would be to not only use them as therapeutic targets, but also extent their value on a preventative level through engineering mechanisms and prevention of EOC in its origin.

Indexed as

FemaleHumansNeoplastic Stem CellsOvarian NeoplasmsEpithelial–mesenchymal transitionOvarian cancerStem cellsVery small embryonic-like stem cells

Identifiers

PMID32200419
OpenAlexW3012943617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.